注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Eyepoint Pharmaceuticals Inc是一家制药公司。该公司的主要候选产品EYP-1901将其Durasert技术的可生物侵蚀配方与酪氨酸激酶抑制剂( TKI )vorolanib相结合,后者已显示出抗血管内皮生长因子(VEGF)活性。该公司有两个商业产品,YUTIQ和DEXYCU。YUTIQ是一种不可侵蚀的玻璃体内植入物,含有长达36个月的氟轻松(FA),适用于治疗影响眼睛后段的慢性非感染性葡萄膜炎。YUTIQ利用其Durasert缓释药物输送技术平台。DEXYCU是治疗术后眼部炎症的指征。DEXYCU利用其Verisome药物递送技术。该公司还在推进YETIQ 50,这是一种为期六个月的影响眼睛后段的非感染性葡萄膜炎治疗,这是补充新药应用(sNDA)策略下失明的原因之一。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Goran A. Ando | 74 | 2018 | Independent Non-Executive Chairman |
Jay S. Duker | 64 | 2020 | President, CEO & Director |
Nancy S. Lurker | 66 | 2016 | Executive Vice-Chairman |
Anat Loewenstein | - | 2023 | Member of Executive Scientific Advisory Board |
Anthony P. Adamis | 64 | 2022 | Independent Director |
Karen Zaderej | 61 | 2022 | Independent Director |
Stuart Duty | 58 | 2023 | Independent Director |
Wendy F. DiCicco | 57 | 2019 | Independent Director |
David Robert Guyer | 64 | 2019 | Independent Director |
Charles C. Wykoff | - | 2021 | Co-Chair of Scientific Advisory Board |
Rishi P. Singh | - | 2021 | Member of Executive Scientific Advisory Board |
Glenn J. Jaffe | - | 2021 | Member of Executive Scientific Advisory Board |
Allen C. Ho | - | 2024 | Member of Scientific Advisory Board |
David S. Boyer | - | 2021 | Member of Executive Scientific Advisory Board |
Carl D. Regillo | - | 2021 | Co- Chairman of Scientific Advisory Board |
Anna Kluczewska | - | - | CEO of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd |
Ye Liu | 52 | 2020 | Director |
Sophie J. Bakri | - | 2021 | Member of Executive Scientific Advisory Board |
Usha Chakravarthy | - | 2024 | Member of Scientific Advisory Board |
Frank G. Holz | - | 2024 | Member of Scientific Advisory Board |
John B. Landis | 71 | 2018 | Interim Head of R&D and Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核